PDS Biotechnology (PDSB) Enterprise Value (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Enterprise Value came in at -$26.7 million in Q4 2025, up 35.93% YoY from -$19.7 million in Q4 2024, and down 1.95% on a QoQ basis from -$26.2 million in Q3 2025.
PDS Biotechnology (PDSB) Enterprise Value (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Enterprise Value data on file, last reported at -$26.7 million in Q4 2025.
- Quarterly Enterprise Value rose 35.93% year-over-year to -$26.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.7 million (up 35.93% YoY) and the FY2025 annual result came in at -$26.7 million, up 35.93% from the prior year.
- Enterprise Value declined to -$26.7 million in Q4 2025, from -$26.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$25.0 million in Q1 2021 to a low of -$74.7 million in Q2 2021.
- A 5-year average of -$53.5 million and a median of -$57.1 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 341.4% — and 2025, when it soared 47.39%.
- Tracing PDSB's Enterprise Value over 5 years: stood at -$65.2 million in 2021, then declined by 13.15% to -$73.8 million in 2022, then advanced by 23.38% to -$56.6 million in 2023, then gained by 26.29% to -$41.7 million in 2024, then jumped by 35.93% to -$26.7 million in 2025.
- The last three Enterprise Value figures came in at -$26.7 million (Q4 2025), -$26.2 million (Q3 2025), and -$31.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 2.12 Bn |
| 10 | PDS Biotechnology | 12.08 Mn | 12.08 Mn | - | -5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.60 Mn |
| Dec 31, 2025 | -26.71 Mn |
| Sep 30, 2025 | -26.20 Mn |
| Jun 30, 2025 | -31.87 Mn |
| Mar 31, 2025 | -40.00 Mn |
| Dec 31, 2024 | -41.69 Mn |
| Sep 30, 2024 | -49.80 Mn |
| Jun 30, 2024 | -57.73 Mn |
| Mar 31, 2024 | -66.60 Mn |
| Dec 31, 2023 | -56.56 Mn |
| Sep 30, 2023 | -54.30 Mn |
| Jun 30, 2023 | -60.60 Mn |
| Mar 31, 2023 | -65.20 Mn |
| Dec 31, 2022 | -73.82 Mn |
| Sep 30, 2022 | -71.60 Mn |
| Jun 30, 2022 | -52.98 Mn |
| Mar 31, 2022 | -58.90 Mn |
| Dec 31, 2021 | -65.24 Mn |
| Sep 30, 2021 | -69.70 Mn |
| Jun 30, 2021 | -74.75 Mn |